Monoamine oxidase A-directed therapy for recurrent prostate cancer hits mark in early trial
Phenelzine, a monoamine oxidase inhibitor, shows therapeutic potential in patients with biochemical recurrent castrate-sensitive prostate cancer, according to the results of a phase II trial.